Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882889 | 0.81 | WDR5 (0.47) | NTRK1ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4880503 | 0.76 | KCNQ2 (0.47) | NTRK1ALDH1A1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL4876069 | 0.71 | ALDH1A1 (0.43) | NTRK1ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11485609 | 0.70 | TGFBR1 (0.57) | ALDH1A1KMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL991856 | 0.69 | NPC1 (0.65) | ALDH1A1KMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL4882676 | 0.69 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL9699916 | 0.69 | PDE10A (0.47) | ALDH1A1SMN1; SMN2TP53MAPK1NPC1 | |
| SCHEMBL14278537 | 0.68 | TGFBR1 (0.52) | ALDH1A1KMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL11474630 | 0.66 | HPGD (0.54) | ALDH1A1KMT2AMEN1SMN1; SMN2TP53 | |
| SCHEMBL4839190 | 0.65 | NPC1 (0.59) | ALDH1A1KMT2AMEN1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-09 | — | — | US | claimed |
| EP-1698335-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | claimed |
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1698335-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | MTNR1A, GSR, NLN | NTRK1 492/4885CNR1 16/4885ALDH1A1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.